ehc-20240930

美國

證券交易委員會

華盛頓特區20549

______________________________

表格 10-Q


☒			根據13或15(d)條款的季度報告 1934年證券交易所法

截至2024年6月30日季度結束 2024年9月30日

或


☐			根據第13或第15(d)條規定的過渡報告 1934年證券交易所法

委員會檔案編號 001-10315

______________________________

康普仕醫療公司

(按其公司章程所規定，公司的正式名稱)


特拉華州			63-0860407
(成立或組織的州或其他轄區)			（聯邦稅號）

9001 Liberty Parkway

伯明翰, 阿拉巴馬 35242

（總部地址）

(205) 967-7116

(申報人的電話號碼)

根據《法案》第12(b)條規定註冊的證券：


每種類別的名稱	交易標的（s）	每個註冊交易所的名稱
每股普通股，面值為0.01美元	EHC	紐約證券交易所

標明並以核准符號表示，證券交易法 1934 年第 13 或 15(d) 條要求之申報已經登記來進行報告了，該報告需涵蓋過去12個月期間 (或是公司需要進行該等報告的較短期間)，並且過去90天內已經受到相關的申報要求。是 ☒否☐

請在核對號勾選方塊以指出是否在過去12個月（或註冊人所需提交此類檔案的較短期間內）按照Regulation S-t的405條款的規定，已電子方式提交所需提交的每個互動數據檔案。是 ☒否☐

請在方框內勾選申報者是否為大型快速申報者、快速申報者、非快速申報者、較小型報告公司或新興成長公司。在《交易所法》第120億2條中，請查看「大型快速申報者」、「快速申報者」、「較小型報告公司」和「新興成長公司」的定義。

大型加速歸檔人

☒

加速歸檔人

☐

非加速申報者

☐

小型報告公司

☐

新興成長型企業

☐

如果是新興成長公司，請勾選，以表示據第13(a)條《交易所法》規定提供的有新修訂的財務會計標准的遵守，已選擇不使用擴展過渡期。☐

選取適用的核對標記，以指明申報人是否為殼公司（依照《交易所法》第120億2條定義）。是☐否☒

截至2024年7月26日，註冊人名下擁有2,177,417,976股普通股。 100,749,546 截至2024年10月22日，扣除庫藏股後，普通股的流通股份。


		頁面
第一部分	財務資訊

項目一。	財務報表 (未經審核)	1
項目二。	管理層對財務狀況及營運結果進行討論及分析	15

第四項。	控制和程序	30

第二部分	其他資訊

項目一。	法律程序	31
項目 1A。	風險因素	31
項目二。	非登記股份證券銷售及所得款項的使用	32
第五項。	其他資訊	32
第六項	展品	32
	展品索引

讀者注意事項

在本報告中使用的術語“encompass health”，“我們”，“我們的”，以及“公司”是指encompass health corporation及其合併子公司，除非另有說明或根據上下文指示。證券交易委員會建議採用這種撰寫風格，並不意味著上市母公司encompass health corporation擁有或經營任何特定資產、業務或財產。本申報書中描述的醫院、運營和業務主要由母公司的子公司擁有和運營。此外，我們在必要時或有助於理解本申報書時使用術語“encompass health corporation”單指encompass health corporation。

關於前瞻性陳述的警語

此季度報告包含歷史資訊，以及涉及已知及未知風險的前瞻性陳述，涉及到未來事件，不時的醫療保險報銷及其他醫療法律法規的變更，我們的業務策略，勞動成本趨勢，我們的股息和股票回購策略，我們的財務計劃，我們的增長計劃，我們未來的財務表現，我們預期的業績，或我們預期的資本支出。在某些情況下，讀者可以通過術語如「可能」、「將」、「應該」、「可能」、「預期」、「計劃」、「預期」、「相信」、「估計」、「預測」、「目標」、「潛在」或「持續」或這些術語的否定形式或其他相應術語來識別前瞻性陳述。這些前瞻性陳述必然是根據當前資訊進行估算，涉及一系列我們無法控制的風險和不確定性。任何前瞻性陳述均基於本報告日期的當前資訊，僅於發布該陳述的日期發表。實際事態或結果可能與這些前瞻性陳述中預期的結果有所不同，這是因為多種因素。儘管無法確定所有這些因素，下文所描述的因素可能導致，並且在COVID-19大流行情況下已經導致實際結果與我們估計的結果存在顯著差異。

•在年度報告Form 10-K第1A項中討論的每個因素風險因素以及本Form 10-Q中其他地方討論的不確定性和因素，包括第I部分第2項“執行概況-主要挑戰”部分管理層對財務狀況和業績的討論與分析在我們不時向SEC提交的其他文件中，或其中引用的文件

•我們在我們的主要業務領域非常專注，特別是在醫療保險規定和補償方面。

•政府或私人支付者對我們的服務進行減少、延遲或暫停報銷，包括我們無法獲得和保留與第三方支付者的有利安排，可能降低我們的收入並對其他營運結果造成不利影響。

•解讀財報制度中對具有退休醫保資格索賠的規定的限制性解釋可能降低我們的收入並對其他經營成果產生不利影響。

•理賠申請須接受各種審計，而這些審計可能導致指稱我們被支付過多或提交不當申請，這些指稱過去曾經且將來將需要我們負擔額外成本以回應索取記錄的要求並捍衛支付的有效性，並退款任何被認定為支付過多的金額。

•政府機構和承包商使用統計抽樣和外推可能會大幅擴大超支或不合規的索賠。

•在過去和將來，與被否決醫療保險報銷索賠相關的行政上及程序上的缺點，包括來自各類醫療保險稽核計劃，可能會延遲或減少我們先前提供服務的報銷金額，甚至透過對於我們來自醫療保險的其他索賠的補繳。

•Efforts to reduce payments to healthcare providers undertaken by third-party payors and conveners could adversely affect our revenues or profitability.

•Changes in our payor mix or the acuity of our patients could reduce our revenues or profitability.

•Changes in the rules and regulations of the healthcare industry at the federal, state, and local levels, including those contemplated now and in the future as part of healthcare reform and deficit reduction (such as the Inpatient Rehabilitation Facility Review Choice Demonstration, the re-basing of payment systems, the introduction of site neutral payments or case-mix weightings across post-acute settings, and other payment system reforms) could decrease revenues and increase the costs of complying with the rules and regulations and have done so in the past from time to time.

•Alternative payment models and value-based purchasing initiatives could decrease our patient volumes and reimbursement rate or increase costs associated with our operations.

•Compliance with the extensive and frequently changing laws and regulations applicable to healthcare providers, including those related to patient care, coding and billing, data privacy and security, consumer protection, anti-trust, and employment practices, requires substantial time, effort and expense, and if we fail to comply, we could incur

penalties and significant costs of investigating and defending asserted claims, whether meritorious or not, or be required to make significant changes to our operations.

•Our inability to maintain proper local, state and federal licensing, including compliance with the Medicare conditions of participation and provider enrollment requirements could decrease our revenues.

•Incidents affecting the proper operation, availability, or security of our or our payors’, vendors’ or partners’ information systems, including the patient information stored there, or business continuity could cause substantial losses and adversely affect our operations and governmental mandates to increase use of electronic records and interoperability exacerbate that risk.

•Any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings, including disclosed and undisclosed qui tam suits, could be difficult to predict and could adversely affect our financial results or condition or our operations, and we could experience increased costs of defending and insuring against alleged professional liability and other claims.

•Our inability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings, productivity improvements arising from the related operations and avoidance of unanticipated difficulties, costs or liabilities that could arise from acquisitions or integrations could adversely affect our financial results or condition.

•Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and potential union activity could increase staffing costs and adversely affect other financial and operating results and has done so in the past.

•Competitive pressures in the healthcare industry, including from large acute-care hospitals that would typically serve as referral sources for us, and our response to those pressures could adversely affect our revenues or other financial results.

•Medicare quality reporting requirements could adversely affect our operating costs or Medicare reimbursement.

•Our inability to provide a consistently high quality of care, including as represented in metrics published by Medicare, could decrease our revenues.

•Our inability to maintain or develop relationships with patient referral sources, including our joint venture hospitals, or managed care payors could decrease our revenues.

•Acute-care hospitals that participate in joint ventures with us may experience, and in the past some have experienced, operational or financial challenges that, in turn, affect our joint venture inpatient rehabilitation hospitals.

•A pandemic, epidemic, or other widespread outbreak of an infectious disease or other public health crisis, and governmental responses to those events, could decrease our patient volumes, pricing, and revenues, lead to staffing and supply shortages and associated cost increases, otherwise interrupt operations, or lead to increased litigation risk and, in the case of the COVID-19 pandemic, has already done so in many instances.

•Regional, particularly Texas or Florida, or global socio-political, weather, or other catastrophic events have previously severely disrupted, and could again in the future disrupt, our business, including indirectly by affecting the patient population and referral sources in our markets.

•Regulatory and other efforts to promote a transition to a lower-carbon economy may result in significant operational and financial challenges for us.

•Our inability to maintain infectious disease prevention and control efforts that are required and effectively minimize the spread among patients and employees could decrease our patient volumes and revenues, lead to staffing shortages or otherwise interrupt operations, or lead to increased litigation risk.

•Our debt and the associated restrictive covenants could have negative consequences for our business and limit our ability to execute aspects of our business plan successfully.

•The price of our common stock could adversely affect our willingness and ability to repurchase shares.

•We may be unable or unwilling to continue to declare and pay dividends on our common stock.

iii

•General conditions in the economy and capital markets, including inflation, any disruption, instability, or uncertainty related to armed conflict or an act of terrorism, a governmental impasse over approval of the United States federal budget or an increase to the debt ceiling, an international trade war, or a sovereign debt crisis could adversely affect our financial results or condition, including access to the capital markets.

The cautionary statements referred to in this section also should be considered in connection with any subsequent written or oral forward-looking statements that may be issued by us or persons acting on our behalf. We undertake no duty to update these forward-looking statements, even though our situation may change in the future. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.

PART I. FINANCIAL INFORMATION

Item 1.Financial Statements (Unaudited)

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
	(In Millions, Except Per Share Data)
Net operating revenues	$	1,351.0	$	1,206.9	$	3,968.2	$	3,554.4
Operating expenses:
Salaries and benefits	732.1		658.6		2,144.2		1,923.8
Other operating expenses	202.4		183.7		596.2		534.3
Occupancy costs	14.4		14.2		42.6		42.3
Supplies	60.6		53.9		176.7		159.7
General and administrative expenses	54.0		49.8		154.7		148.6
Depreciation and amortization	78.4		67.3		221.6		203.8


Total operating expenses	1,141.9		1,027.5		3,336.0		3,012.5
Loss on early extinguishment of debt	0.4		—		0.4		—
Interest expense and amortization of debt discounts and fees	34.9		35.9		104.4		108.6
Other income	(9.3)		(0.5)		(18.0)		(6.8)
Equity in net income of nonconsolidated affiliates	(0.7)		(1.0)		(2.8)		(2.3)
Income from continuing operations before income tax expense	183.8		145.0		548.2		442.4
Provision for income tax expense	36.0		30.3		112.6		95.0
Income from continuing operations	147.8		114.7		435.6		347.4
Loss from discontinued operations, net of tax	(0.7)		(1.3)		(3.2)		(3.5)
Net and comprehensive income	147.1		113.4		432.4		343.9


Less: Net and comprehensive income attributable to noncontrolling interests	(38.9)		(28.1)		(97.6)		(79.5)
Net and comprehensive income attributable to Encompass Health	$	108.2	$	85.3	$	334.8	$	264.4



Weighted average common shares outstanding:
Basic	99.9		99.5		99.9		99.5
Diluted	102.1		101.4		102.2		101.1
Earnings per common share:
Basic earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$	1.09	$	0.86	$	3.36	$	2.68
Discontinued operations	(0.01)		(0.01)		(0.03)		(0.04)
Net income	$	1.08	$	0.85	$	3.33	$	2.64
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$	1.07	$	0.85	$	3.31	$	2.65
Discontinued operations	(0.01)		(0.01)		(0.03)		(0.03)
Net income	$	1.06	$	0.84	$	3.28	$	2.62

Amounts attributable to Encompass Health common shareholders:
Income from continuing operations	$	108.9	$	86.6	$	338.0	$	267.9
Loss from discontinued operations, net of tax	(0.7)		(1.3)		(3.2)		(3.5)
Net income attributable to Encompass Health	$	108.2	$	85.3	$	334.8	$	264.4

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)


	September 30, 2024		December 31, 2023
	(In Millions)
Assets
Current assets:
Cash and cash equivalents	$	147.8	$	69.1
Restricted cash	51.1		35.1
Accounts receivable	576.4		611.6
Other current assets	158.6		126.0
Total current assets	933.9		841.8
Property and equipment, net	3,523.7		3,301.0
Operating lease right-of-use assets	209.7		208.5
Goodwill	1,284.0		1,281.3
Intangible assets, net	296.2		278.2

Other long-term assets	210.9		191.6
Total assets(1)	$	6,458.4	$	6,102.4
Liabilities and Shareholders’ Equity
Current liabilities:
Current portion of long-term debt	$	233.0	$	24.8
Current operating lease liabilities	26.5		24.1
Accounts payable	170.3		170.0

Accrued expenses and other current liabilities	467.6		437.5
Total current liabilities	897.4		656.4
Long-term debt, net of current portion	2,344.5		2,687.8
Long-term operating lease liabilities	195.5		196.1
Deferred income tax liabilities	97.1		87.0
Other long-term liabilities	198.3		177.9
Total liabilities(1)	3,732.8		3,805.2
Commitments and contingencies

Redeemable noncontrolling interests	56.5		42.0
Shareholders’ equity:
Encompass Health shareholders’ equity	1,959.8		1,647.5
Noncontrolling interests	709.3		607.7
Total shareholders’ equity	2,669.1		2,255.2
Total liabilities(1) and shareholders’ equity	$	6,458.4	$	6,102.4

(1)Our consolidated assets as of September 30, 2024 and December 31, 2023 include total assets of variable interest entities of $213.8 million and $207.7 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of September 30, 2024 and December 31, 2023 include total liabilities of the variable interest entities of $44.3 million and $42.2 million, respectively. See Note 2, Variable Interest Entities.

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited)


	Three Months Ended September 30, 2024
	(In Millions)
	Encompass Health Common Shareholders
	Number of Common Shares Outstanding	Common Stock		Capital in Excess of Par Value		Accumulated Income		Treasury Stock		Noncontrolling Interests		Total
Balance at beginning of period	100.7	$	1.2	$	1,806.8	$	602.3	$	(570.9)	$	642.0	$	2,481.4
Net income	—	—		—		108.2		—		37.7		145.9


Dividends declared ($0.17 per share)	—	—		0.1		(17.3)		—		—		(17.2)

Stock-based compensation	—	—		12.9		—		—		—		12.9


Distributions declared	—	—		—		—		—		(36.4)		(36.4)
Capital contributions from consolidated affiliates	—	—		—		—		—		96.9		96.9


Repurchases of common stock in open market	(0.1)	—		—		—		(6.8)		—		(6.8)


Contribution of our hospital to consolidated joint venture	—	—		22.9		—		—		(30.8)		(7.9)
Other	0.2	—		(4.5)		—		4.9		(0.1)		0.3
Balance at end of period	100.8	$	1.2	$	1,838.2	$	693.2	$	(572.8)	$	709.3	$	2,669.1


	Three Months Ended September 30, 2023
	(In Millions)
	Encompass Health Common Shareholders
	Number of Common Shares Outstanding	Common Stock		Capital in Excess of Par Value		Accumulated Income		Treasury Stock		Noncontrolling Interests		Total
Balance at beginning of period	100.2	$	1.2	$	1,755.0	$	264.6	$	(545.5)	$	542.4	$	2,017.7
Net income	—	—		—		85.3		—		26.2		111.5

Receipt of treasury stock	—	—		—		—		(0.4)		—		(0.4)
Dividends declared ($0.15 per share)	—	—		0.4		(15.6)		—		—		(15.2)


Stock-based compensation	—	—		13.7		—		—		—		13.7


Distributions declared	—	—		—		—		—		(28.8)		(28.8)
Capital contributions from consolidated affiliates	—	—		—		—		—		49.0		49.0





Other	—	—		2.5		—		(0.8)		(1.5)		0.2
Balance at end of period	100.2	$	1.2	$	1,771.6	$	334.3	$	(546.7)	$	587.3	$	2,147.7

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Shareholders’ Equity (Continued)

(Unaudited)


	Nine Months Ended September 30, 2024
	(In Millions)
	Encompass Health Common Shareholders
	Number of Common Shares Outstanding	Common Stock		Capital in Excess of Par Value		Accumulated Income		Treasury Stock		Noncontrolling Interests		Total
Balance at beginning of period	100.3	$	1.2	$	1,787.0	$	406.5	$	(547.2)	$	607.7	$	2,255.2
Net income	—	—		—		334.8		—		93.4		428.2
Receipt of treasury stock	(0.2)	—		—		—		(12.1)		—		(12.1)
Dividends declared ($0.47 per share)	—	—		0.3		(48.1)		—		—		(47.8)

Stock-based compensation	—	—		35.8		—		—		—		35.8


Distributions declared	—	—		—		—		—		(94.5)		(94.5)
Capital contributions from consolidated affiliates	—	—		—		—		—		133.5		133.5


Repurchases of common stock in open market	(0.3)	—		—		—		(23.6)		—		(23.6)


Contribution of our hospital to consolidated joint venture	—	—		22.9		—		—		(30.8)		(7.9)
Other	1.0	—		(7.8)		—		10.1		—		2.3
Balance at end of period	100.8	$	1.2	$	1,838.2	$	693.2	$	(572.8)	$	709.3	$	2,669.1


	Nine Months Ended September 30, 2023
	(In Millions)
	Encompass Health Common Shareholders
	Number of Common Shares Outstanding	Common Stock		Capital in Excess of Par Value		Accumulated Income		Treasury Stock		Noncontrolling Interests		Total
Balance at beginning of period	99.8	$	1.1	$	1,730.2	$	115.7	$	(536.7)	$	516.0	$	1,826.3
Net income	—	—		—		264.4		—		73.3		337.7

Receipt of treasury stock	(0.1)	—		—		—		(8.1)		—		(8.1)
Dividends declared ($0.45 per share)	—	—		0.4		(45.8)		—		—		(45.4)

Stock-based compensation	—	—		37.2		—		—		—		37.2


Distributions declared	—	—		—		—		—		(87.5)		(87.5)
Capital contributions from consolidated affiliates	—	—		—		—		—		87.0		87.0





Other	0.5	0.1		3.8		—		(1.9)		(1.5)		0.5
Balance at end of period	100.2	$	1.2	$	1,771.6	$	334.3	$	(546.7)	$	587.3	$	2,147.7

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Nine Months Ended September 30,
	2024		2023
	(In Millions)
Cash flows from operating activities:
Net income	$	432.4	$	343.9
Loss from discontinued operations, net of tax	3.2		3.5
Adjustments to reconcile net income to net cash provided by operating activities—

Depreciation and amortization	221.6		203.8



Stock-based compensation	35.8		37.2
Deferred tax expense (benefit)	2.1		(2.9)


Other, net	13.5		10.0
Change in assets and liabilities, net of acquisitions—
Accounts receivable	29.1		20.7
Other assets	(43.3)		(4.1)
Accounts payable	1.4		(0.2)
Accrued payroll	(2.6)		24.1
Accrued interest payable	(19.2)		(19.1)
Other liabilities	53.7		37.5
Net cash used in operating activities of discontinued operations	(3.7)		(4.6)
Total adjustments	288.4		302.4
Net cash provided by operating activities	724.0		649.8
Cash flows from investing activities:

Purchases of property, equipment, and intangible assets	(443.8)		(371.4)

Purchase of restricted investments	(20.0)		(21.1)
Proceeds from sale of restricted investments	17.9		7.0

Other, net	(3.7)		(9.2)

Net cash used in investing activities	(449.6)		(394.7)




Cash flows from financing activities:

Principal borrowings on notes	15.0		20.0
Principal payments on debt, including pre-payments	(153.4)		(6.3)
Borrowings on revolving credit facility	50.0		60.0
Payments on revolving credit facility	(50.0)		(115.0)
Principal payments under finance lease obligations	(16.2)		(35.9)

Taxes paid on behalf of employees for shares withheld	(12.1)		(8.1)
Contributions from noncontrolling interests of consolidated affiliates	139.7		54.7
Dividends paid on common stock	(45.8)		(45.5)
Distributions paid to noncontrolling interests of consolidated affiliates	(85.5)		(91.9)
Repurchases of common stock, including fees and expenses	(23.6)		—

Other, net	2.2		0.7

Net cash used in financing activities	(179.7)		(167.3)





Increase in cash, cash equivalents, and restricted cash	94.7		87.8
Cash, cash equivalents, and restricted cash at beginning of period	104.2		53.4
Cash, cash equivalents, and restricted cash at end of period	$	198.9	$	141.2

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Continued)

(Unaudited)


	Nine Months Ended September 30,
	2024		2023
	(In Millions)
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period	$	69.1	$	21.8
Restricted cash at beginning of period	35.1		31.6


Cash, cash equivalents, and restricted cash at beginning of period	$	104.2	$	53.4

Cash and cash equivalents at end of period	$	147.8	$	99.7
Restricted cash at end of period	51.1		41.5


Cash, cash equivalents, and restricted cash at end of period	$	198.9	$	141.2

Supplemental schedule of noncash operating, investing, and financing activities:
Property and equipment additions through finance leases	$	—	$	21.4
Accrued purchases of property, equipment, and intangible assets	3.1		32.7
Operating lease additions and adjustments	25.6		7.9
Joint venture contributions	11.8		32.2

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

Encompass Health Corporation and Subsidiaries

Notes to Condensed Consolidated Financial Statements

1.Basis of Presentation

Encompass Health Corporation (the “Company” or “Encompass Health”), incorporated in Delaware in 1984, including its subsidiaries, is a provider of inpatient rehabilitation services. Our national network of inpatient rehabilitation hospitals stretches across 38 states and Puerto Rico, with concentrations of hospitals in Florida and Texas. As of September 30, 2024, we operate 165 inpatient rehabilitation hospitals. We are the sole owner of 100 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 65 jointly owned hospitals.

The accompanying unaudited condensed consolidated financial statements of Encompass Health Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Encompass Health’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission on February 28, 2024 (the “2023 Form 10‑K”). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading. Certain prior year amounts may have been reclassified for comparative purposes to conform to the current-year financial statement presentation.

The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented.

Net Operating Revenues—

Our Net operating revenues disaggregated by payor source are as follows (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Medicare	$	883.3	$	786.5	$	2,573.9	$	2,306.1
Medicare Advantage	220.9		191.7		671.4		576.6
Managed care	148.1		135.4		430.8		396.4
Medicaid	46.1		49.2		134.4		145.6
Other third-party payors	10.0		10.6		30.8		32.2
Workers’ compensation	7.0		6.6		21.0		19.6
Patients	4.1		3.8		11.8		10.4
Other income	31.5		23.1		94.1		67.5
Total	$	1,351.0	$	1,206.9	$	3,968.2	$	3,554.4

See Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2023 Form 10-K for our policy related to Net operating revenues.

Encompass Health Corporation and Subsidiaries

Notes to Condensed Consolidated Financial Statements

Noncontrolling Interests in Consolidated Affiliates—

Effective July 1, 2024, we expanded our existing joint venture with Piedmont Healthcare (“Piedmont”), which we control, by contributing the assets and operations of our previously wholly-owned 70-bed hospital in Augusta, Georgia. Piedmont contributed approximately $90 million on July 1, 2024, which indirectly resulted in Piedmont obtaining a 50% ownership interest in the hospital. As a result of this transaction, we recorded a post-tax gain of $22.9 million increasing Capital in excess of par value on the condensed consolidated statement of shareholders’ equity for the nine months ending September 30, 2024. The contribution from Piedmont is included in Contributions from noncontrolling interests of consolidated affiliates on the condensed consolidated statement of cash flows for the nine months ended September 30, 2024.

On July 1, 2023, we entered into a joint venture agreement with the University of Maryland Rehabilitation Institute of Southern Maryland, LLC (“UM Rehab”) to operate our previously wholly-owned 60-bed hospital in Bowie, Maryland. As a condition of the joint venture agreement, UM Rehab paid $26.3 million on June 30, 2023, for a 50% ownership interest in the hospital which became effective on July 1, 2023. This payment is included in Contributions from noncontrolling interests of consolidated affiliates on the condensed consolidated statement of cash flows for the nine months ended September 30, 2023.

Recent Accounting Pronouncements—

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires all public entities, including entities with a single reportable segment, to provide disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity’s CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. ASU 2023-07 is effective for our annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025. Early adoption is permitted with retrospective application required for all prior periods presented in the financial statements. We are currently evaluating the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which intends to improve the transparency of income tax disclosures by requiring companies to (1) disclose consistent categories and greater disaggregation of information in the effective rate reconciliation and (2) provide information on income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We are required to apply the guidance prospectively but have the option to apply it retrospectively. We are currently evaluating the requirements of this standard and any potential impact it may have on our condensed consolidated financial statements.

We do not believe any other recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.

Encompass Health Corporation and Subsidiaries

Notes to Condensed Consolidated Financial Statements

2.Variable Interest Entities

As of September 30, 2024 and December 31, 2023, we consolidated eight limited partnership-like entities that are variable interest entities (“VIEs”) and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 75.0% as of September 30, 2024. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.

The carrying amounts and classifications of the consolidated VIEs’ assets and liabilities, which are included in our condensed consolidated balance sheets, are as follows (in millions):


	September 30, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	1.2	$	0.2
Accounts receivable	33.2		36.7
Other current assets	16.5		5.0

Total current assets	50.9		41.9
Property and equipment, net	135.0		128.8
Operating lease right-of-use assets	1.3		1.4
Goodwill	15.9		15.9
Intangible assets, net	1.0		1.2
Other long-term assets	9.7		18.5

Total assets	$	213.8	$	207.7
Liabilities
Current liabilities:
Current portion of long-term debt	$	0.9	$	0.9

Accounts payable	6.5		7.6
Accrued expenses and other current liabilities	22.6		18.7

Total current liabilities	30.0		27.2
Long-term debt, net of current portion	12.9		13.6
Long-term operating lease liabilities	1.4		1.4

Total liabilities	$	44.3	$	42.2

Encompass Health Corporation and Subsidiaries

Notes to Condensed Consolidated Financial Statements

3.Long-term Debt

Our long-term debt outstanding consists of the following (in millions):


	September 30, 2024		December 31, 2023
Credit Agreement—
Advances under revolving credit facility	$	—	$	—

Bonds payable—
5.75% Senior Notes due 2025	199.5		348.5
4.50% Senior Notes due 2028	787.5		785.0
4.75% Senior Notes due 2030	783.5		781.5
4.625% Senior Notes due 2031	392.3		391.5
Other notes payable	90.7		66.0
Finance lease obligations	324.0		340.1
	2,577.5		2,712.6
Less: Current portion	(233.0)		(24.8)
Long-term debt, net of current portion	$	2,344.5	$	2,687.8

The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):


	Face Amount		Net Amount
October 1 through December 31, 2024	$	6.7	$	6.7
2025	237.5		237.0
2026	37.3		37.3
2027	44.4		44.4
2028	833.0		820.5
2029	41.7		41.7
Thereafter	1,414.2		1,389.9
Total	$	2,614.8	$	2,577.5

In August 2024, we redeemed $150 million of the outstanding principal balance of our 5.75% Senior Notes due 2025 (the “2025 Notes”) using cash on hand. Pursuant to the terms of the 2025 Notes, this optional redemption was made at a price of par. As a result of this redemption, we recorded a $0.4 million Loss on early extinguishment of debt during the three months ended September 30, 2024.

On October 22, 2024, we issued notice for redemption of $100 million of the outstanding principal balance of our 2025 Notes. The associated redemption date will be November 21, 2024, and the redemption price will be 100.0% of par, plus accrued and unpaid interest pursuant to the terms of the 2025 Notes. We plan to use cash on hand to fund the redemption. As a result of this redemption, we expect to record an approximate $0.2 million Loss on early extinguishment of debt in the fourth quarter of 2024.

In September 2023, we purchased our Treasure Coast hospital real estate in Vero Beach, Florida from Ocean Health Associates, LTD. (“Ocean Health”) for $21.4 million. Prior to the purchase, we leased the real estate from Ocean Health. As a result of our determination in the third quarter of 2023, the lease classification was changed from an operating lease to a financing lease. The $21.4 million payment is included in Principal payments under finance lease obligations on the condensed consolidated statement of cash flows for the nine months ended September 30, 2023.

Encompass Health Corporation and Subsidiaries

Notes to Condensed Consolidated Financial Statements

4.Redeemable Noncontrolling Interests

The following is a summary of the activity related to our Redeemable noncontrolling interests (in millions):


	Nine Months Ended September 30,
	2024		2023
Balance at beginning of period	$	42.0	$	35.6
Net income attributable to noncontrolling interests	4.2		6.2
Distributions declared	(7.7)		(0.3)
Contribution to joint venture	18.0		—





Balance at end of period	$	56.5	$	41.5

The following table reconciles the net income attributable to nonredeemable Noncontrolling interests, as recorded in the shareholders’ equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net and comprehensive income attributable to noncontrolling interests presented in the condensed consolidated statements of comprehensive income (in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net income attributable to nonredeemable noncontrolling interests	$	37.7	$	26.2	$	93.4	$	73.3
Net income attributable to redeemable noncontrolling interests	1.2		1.9		4.2		6.2
Net income attributable to noncontrolling interests	$	38.9	$	28.1	$	97.6	$	79.5

See also Note 5, Fair Value Measurements.

5.Fair Value Measurements

Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):


			Fair Value Measurements at Reporting Date Using
As of September 30, 2024	Fair Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Valuation Technique (1)



Equity securities (2)	$	131.0	$	4.4	$	126.6	$	—	M

Redeemable noncontrolling interests	56.5		—		—		56.5		I
As of December 31, 2023

Equity securities (2)	$	126.2	$	4.0	$	122.2	$	—	M

Redeemable noncontrolling interests	42.0		—		—		42.0		I

(1) The two valuation techniques are: market approach (M) and income approach (I).

(2) As of September 30, 2024, $40.6 million are included in Other current assets and $90.4 million are included in Other long-term assets in the condensed consolidated balance sheet. As of December 31, 2023, $37.6 million are included in Other current assets and $88.6 million are included in Other long-term assets in the condensed consolidated balance sheet.

There are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the three and nine months ended September 30, 2024 and 2023, we did not record any material gains or losses related to these assets.

Encompass Health Corporation and Subsidiaries

Notes to Condensed Consolidated Financial Statements

As discussed in Note 1, Summary of Significant Accounting Policies, “Fair Value Measurements,” to the consolidated financial statements accompanying the 2023 Form 10‑K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):


	As of September 30, 2024				As of December 31, 2023
	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Long-term debt:


5.75% Senior Notes due 2025	$	199.5	$	199.5	$	348.5	$	349.3
4.50% Senior Notes due 2028	787.5		784.2		785.0		763.6
4.75% Senior Notes due 2030	783.5		781.7		781.5		755.0
4.625% Senior Notes due 2031	392.3		383.0		391.5		369.4
Other notes payable	90.7		90.7		66.0		66.0
Financial commitments:
Letters of credit	—		36.3		—		31.9

Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies, “Fair Value Measurements,” to the consolidated financial statements accompanying the 2023 Form 10‑K.

6.Share-Based Payments

During the nine months ended September 30, 2024, we issued a total of 0.5 million restricted stock awards to members of our management team and our board of directors. Of the restricted stock awards issued to members of our management team, 0.2 million contain only a service condition, while the remainder contain a service and/or performance condition as well as a market condition for certain members of management. For the awards that include a performance and market condition, the number of shares that will ultimately be granted to employees may vary based on the Company’s performance during the applicable three-year performance measurement period and the applicable three-year market condition measurement period. Additionally, we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note 1, Summary of Significant Accounting Policies, and Note 14, Share-Based Payments, to the consolidated financial statements accompanying the 2023 Form 10‑K.

7.Income Taxes

Our Provision for income tax expense of $36.0 million and $112.6 million for the three and nine months ended September 30, 2024, respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rate partially offset by tax benefits resulting from share-based compensation windfalls. Our Provision for income tax expense of $30.3 million and $95.0 million for the three and nine months ended September 30, 2023, respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rate.

Encompass Health Corporation and Subsidiaries

Notes to Condensed Consolidated Financial Statements

8.Earnings per Common Share

The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Basic:
Numerator:
Income from continuing operations	$	147.8	$	114.7	$	435.6	$	347.4
Less: Net income attributable to noncontrolling interests included in continuing operations	(38.9)		(28.1)		(97.6)		(79.5)
Less: Income allocated to participating securities	(0.7)		(0.6)		(2.0)		(1.8)

Income from continuing operations attributable to Encompass Health common shareholders	108.2		86.0		336.0		266.1



Loss from discontinued operations attributable to Encompass Health common shareholders	(0.7)		(1.3)		(3.2)		(3.5)
Net income attributable to Encompass Health common shareholders	$	107.5	$	84.7	$	332.8	$	262.6
Denominator:
Basic weighted average common shares outstanding	99.9		99.5		99.9		99.5
Basic earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$	1.09	$	0.86	$	3.36	$	2.68
Discontinued operations	(0.01)		(0.01)		(0.03)		(0.04)
Net income	$	1.08	$	0.85	$	3.33	$	2.64

Diluted:
Numerator:
Income from continuing operations	$	147.8	$	114.7	$	435.6	$	347.4
Less: Net income attributable to noncontrolling interests included in continuing operations	(38.9)		(28.1)		(97.6)		(79.5)


Income from continuing operations attributable to Encompass Health common shareholders	108.9		86.6		338.0		267.9


Loss from discontinued operations attributable to Encompass Health common shareholders	(0.7)		(1.3)		(3.2)		(3.5)
Net income attributable to Encompass Health common shareholders	$	108.2	$	85.3	$	334.8	$	264.4
Denominator:
Diluted weighted average common shares outstanding	102.1		101.4		102.2		101.1
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$	1.07	$	0.85	$	3.31	$	2.65
Discontinued operations	(0.01)		(0.01)		(0.03)		(0.03)
Net income	$	1.06	$	0.84	$	3.28	$	2.62

Encompass Health Corporation and Subsidiaries

Notes to Condensed Consolidated Financial Statements

The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):


	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Basic weighted average common shares outstanding	99.9	99.5	99.9	99.5


Restricted stock awards, dilutive stock options, and restricted stock units	2.2	1.9	2.3	1.6
Diluted weighted average common shares outstanding	102.1	101.4	102.2	101.1

See Note 17, Earnings per Common Share, to the consolidated financial statements accompanying the 2023 Form 10‑K for additional information related to our common stock.

9.Contingencies and Other Commitments

We provide services in the highly regulated healthcare industry. Furthermore, operating inpatient rehabilitation hospitals requires significant staffing and involves intensive therapy for individuals suffering from significant physical or cognitive disabilities or injuries. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.

Other Matters—

The False Claims Act allows private citizens, called “relators,” to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as “whistleblower” or “qui tam” actions, can involve significant monetary damages, fines, attorneys’ fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. Qui tam cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a qui tam action may remain unaware of the existence of a sealed complaint or its specific claims for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that qui tam lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed qui tam cases brought pursuant to the False Claims Act.

It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the United States Department of Health and Human Services Office of Inspector General and the Centers for Medicare & Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, and may in the future result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.

Other Commitments—

We are a party to service and other contracts in connection with conducting our business. Minimum amounts due under these agreements are $19.7 million for the remainder of 2024, $43.5 million in 2025, $31.6 million in 2026, $26.1 million in 2027, $22.9 million in 2028, and $64.1 million thereafter. These contracts primarily relate to software licensing and support and contract services.

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) relates to Encompass Health Corporation and its subsidiaries and should be read in conjunction with our condensed consolidated financial statements included under Part I, Item 1, Financial Statements (Unaudited), of this report. In addition, the following MD&A should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2023, Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, Part I, Item 1, Business, and Item 1A, Risk Factors, included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed on February 28, 2024 (collectively, the “2023 Form 10‑K”).

This MD&A is designed to provide the reader with information that will assist in understanding our condensed consolidated financial statements, the changes in certain key items in those financial statements from period to period, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our condensed consolidated financial statements. See “Cautionary Statement Regarding Forward-Looking Statements” beginning on page ii of this report, which is incorporated herein by reference for a description of important factors that could cause actual results to differ from expected results. See also Item 1A, Risk Factors, of this report and to the 2023 Form 10‑K.

Executive Overview

Our Business

We are the nation’s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment on an inpatient basis. We operate hospitals in 38 states and Puerto Rico, with concentrations in Florida and Texas. As of September 30, 2024, we operate 165 inpatient rehabilitation hospitals. For additional information about our business, see Item 1, Business, and Item 1A, Risk Factors, of the 2023 Form 10‑K.

2024 Overview

During the three and nine months ended September 30, 2024, Net operating revenues increased 11.9% and 11.6%, respectively, over the same periods of 2023 due primarily to volume growth. See “Results of Operations” section of this Item for additional volume information.

In our continued development and expansion efforts during 2024, we:

•began operating our new 50-bed inpatient rehabilitation hospital in Kissimmee, Florida in May 2024;

•began operating our new 40-bed inpatient rehabilitation hospital in Atlanta, Georgia with our joint venture partner Piedmont in May 2024;

•began operating our new 40-bed inpatient rehabilitation hospital in Louisville, Kentucky with our joint venture partner Baptist Health in June 2024;

•began operating our new 50-bed inpatient rehabilitation hospital in Johnston, Rhode Island in July 2024;

•began operating our new 39-bed inpatient rehabilitation hospital in Fort Mill, South Carolina in September 2024;

•expanded our capacity by adding 125 new beds to existing hospitals (inclusive of our new 40-bed satellite inpatient rehabilitation hospital in Ballwin, Missouri which began operating in May 2024); and

•announced or continued the development of the following hospitals:


	Expected open date	Number of New Beds
		2024	2025	2026
De novo projects(1)
Houston, Texas	4Q24	61	—	—
Athens, Georgia(2)	1Q25	—	40	—
Fort Myers, Florida(2)	2Q25	—	60	—
Daytona Beach, Florida	2Q25	—	50	—
Danbury, Connecticut	3Q25	—	40	—
Lake Worth, Florida	4Q25	—	50	—
St. Petersburg, Florida	4Q25	—	50	—
Amarillo, Texas	4Q25	—	50	—
Irmo, South Carolina		—	—	50
Concordville, Pennsylvania		—	—	50
Loganville, Georgia(2)		—	—	40
Norristown, Pennsylvania		—	—	50
Avondale, Arizona		—	—	60
San Antonio, Texas		—	—	50
Palm Beach Gardens, Florida		—	—	50
Remote and satellite hospitals (included in bed additions)(1)
Wildwood, Florida (in The Villages, Florida)	3Q25	—	50	—
Other bed additions		~110	~80	~80

(1) Opening dates are tentative

(2) Expected joint venture

We also continued our shareholder distributions during the nine months ended September 30, 2024 by paying a quarterly cash dividend of $0.15 per share on our common stock in January 2024, April 2024, and July 2024, respectively. On July 24, 2024, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.17 per share, that was paid on October 15, 2024 to stockholders of record on October 1, 2024. On October 17, 2024, our board of directors declared a cash dividend of $0.17 per share, payable on January 15, 2025 to stockholders of record on January 2, 2025. In addition, we repurchased 0.3 million shares of our common stock in the open market for $23.6 million during the nine months ended September 30, 2024. For additional information see the “Liquidity and Capital Resources” section of this Item.

Business Outlook

We remain highly optimistic regarding the intermediate and long-term prospects of our business. Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future, reaching approximately 73 million people over the age of 65 by 2030. More specifically, the average age of our Medicare patients is approximately 77, and the population group ranging in ages from 75 to 79 is expected to grow at approximately 5% per year through 2026. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, inpatient rehabilitation services.

We are committed to delivering high-quality, cost-effective patient care. As the nation’s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals, we believe we differentiate ourselves from our competitors based on, among other things, the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. We also believe our competitive strengths discussed in Item 1, Business, “Competitive Strengths,” of the 2023 Form 10‑K, give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs.

The healthcare industry faces the prospect of ongoing efforts to transform the healthcare system to coordinated care delivery and payment models. The nature, timing and extent of that transformation remains uncertain, as the development and implementation of new care delivery and payment systems will require significant time and resources. Our goal is to position the Company in a prudent manner to be responsive to industry shifts. We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis. We have been disciplined in creating a capital structure that is flexible with no significant debt maturities in 2024. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our ability to adapt to changes in reimbursement, sustain our business model, and grow through de novo hospitals and bed additions. See also Item 1, Business, “Competitive Strengths” and “Strategy and 2024 Strategic Priorities” of the 2023 Form 10‑K.

Key Challenges

Healthcare is a highly regulated industry facing many well-publicized regulatory and reimbursement challenges. Medicare reimbursement for inpatient rehabilitation facilities (“IRFs”) has recently undergone significant changes. The future of many aspects of healthcare regulation generally and Medicare reimbursement specifically remains uncertain. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe we have the necessary capabilities—change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities—to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so. For a detailed discussion of the challenges we face, see Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Executive Overview—Key Challenges” of the 2023 Form 10‑K.

As we continue to execute our business plan, the following are some of the key challenges we face.

•Operating in a Highly Regulated Industry. We are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. More specifically, because Medicare comprises a significant portion of our Net operating revenues, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. These rules and regulations have affected, or could in the future affect, our business activities by having an impact on the reimbursement we receive for services provided or the costs of compliance, mandating new documentation standards, requiring additional licensure or certification, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and limiting our ability to enter new markets or add new capacity to existing hospitals. See Item 1, Business, “Regulation,” Item 1A, Risk Factors, “Reimbursement Risks” and “Other Regulatory Risks” of the 2023 Form 10‑K for detailed discussions of the most important regulations we face and our programs intended to ensure we comply with those regulations.

•Changes in Medicare Reimbursement and Regulatory Requirements for Operating IRFs. On July 31, 2024, the Centers for Medicare & Medicaid Services (“CMS”) released its notice of final rulemaking for fiscal year 2025 for IRFs (the “2025 Final Rule”) under the inpatient rehabilitation facility prospective payment system. The 2025 Final Rule will implement a net 3.0% market basket increase (market basket update of 3.5% reduced by a productivity adjustment of 0.5%) effective for discharges between October 1, 2024 and September 30, 2025. The 2025 Final Rule also includes changes that impact our hospital-by-hospital base rate for Medicare reimbursement. Such changes include, but are not limited to, revisions to the wage index, updates to outlier payments, and updates to the case-mix group relative weights and average lengths of stay values. Based on our analysis that utilizes the acuity of our patients annualized over a twelve-month period ended June 30, 2024, our experience with outlier payments over this same time frame, and other factors, we believe the 2025 Final Rule will result in a net increase to our Medicare payment rates of approximately 3.3% effective October 1, 2024.

Beginning August 21, 2023, IRFs located in Alabama began participation in CMS’s five-year review choice demonstration (“RCD”), under which Medicare reimbursement claims are assessed for compliance with applicable coverage and clinical documentation requirements. On March 1, 2024, CMS announced the expansion of RCD, effective June 17, 2024, to include IRFs located in Pennsylvania and billing to a certain Medicare Administrative Contractor (“MAC”). We do not bill to this MAC, so we are not subject to RCD in Pennsylvania at this time. CMS plans to expand RCD further to Texas and California, but the timing for doing so is not known. We operate 47 inpatient rehabilitation hospitals (representing approximately 29% of our IRF Medicare claims) in the four RCD states. CMS has also announced it will expand RCD to include additional IRFs, but the timing and sequence for such expansion is not known.

Under RCD, participating IRFs have an initial choice between pre-claim or post-payment review of 100% of Medicare claims submitted to demonstrate compliance with applicable requirements during the first six-month review period or cycle. We elected the pre-claim review option for our IRFs in Alabama for the first cycle. Under the pre-claim review choice, services can begin prior to the submission of the review request and continue while the decision is being made. The pre-claim review request with required documentation must be submitted, reviewed, and approved before the final claim is paid. If a certain percentage of the claims reviewed are found to be valid, the IRF may then opt out of the 100% review. For the first cycle ending in February 2024, that validation percentage was 80% or greater. The validation percentages for cycles two and three are 85% or greater and 90% or greater, respectively. In opting out, the IRF may elect spot prepayment reviews of samples consisting of 5% of total claims or selective post-payment review of a statistically valid random sample. Our claim validation rate for cycle one exceeded 80% at our IRFs in Alabama. For cycle two, which began on May 1, 2024, we elected not to opt out, so our IRFs in Alabama remain subject to the 100% pre-claim review. We cannot predict the impact, if any, RCD may have on the collectability of our Medicare claims over its five-year term and ultimately our financial position, results of operations, and cash flows.

•Maintaining Strong Volume Growth. Various factors, including competition and increasing regulatory and administrative burdens, may impact our ability to maintain and grow our hospital volumes. In any particular market, we may encounter competition from local or national entities with longer operating histories or other competitive advantages, such as acute-care hospitals who provide post-acute services similar to ours or other post-acute providers with relationships with referring acute-care hospitals or physicians. Aggressive payment review practices by Medicare contractors, aggressive enforcement of regulatory policies by government agencies, and restrictive or burdensome rules, regulations or statutes governing admissions practices may lead us to not accept patients who would be appropriate for and would benefit from the services we provide. In addition, from time to time, we must get regulatory approval to expand our services and locations in states with certificate of need laws. This approval may be withheld or take longer than expected. In the case of new-store volume growth, the addition of hospitals to our portfolio also may be difficult and take longer than expected.

•Recruiting and Retaining High-Quality Personnel. Recruiting and retaining qualified personnel, including management, for our inpatient hospitals remain a high priority for us. We attempt to maintain a comprehensive compensation and benefits package that allows us to remain competitive in this challenging staffing environment while remaining consistent with our goal of providing high-quality, cost-effective care. Additionally, our operations have been affected and may in the future be affected by staffing shortages. In recent years, staffing shortages and competition have resulted in increased labor costs, including significant sign-on and shift bonuses, and increased use of contract labor. See Item 1A, Risk Factors, of the 2023 Form 10‑K for further discussion of competition for staffing, shortages of qualified personnel, and other factors that may increase our labor costs and constrain our ability to take new patients.

We remain confident in the prospects of our business based on the increasing demands for the services we provide to an aging population. This confidence is further supported by our strong financial foundation and the substantial investments we have made in our business. We have a proven track record of working through difficult situations, and we believe in our ability to overcome current and future challenges.

Results of Operations

Payor Mix

We derived consolidated Net operating revenues from the following payor sources:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Medicare	65.4	%	65.2	%	64.8	%	64.8	%
Medicare Advantage	16.4	%	15.9	%	16.9	%	16.2	%
Managed care	11.0	%	11.2	%	10.9	%	11.2	%
Medicaid	3.4	%	4.1	%	3.4	%	4.1	%
Other third-party payors	0.7	%	0.9	%	0.8	%	0.9	%
Workers’ compensation	0.5	%	0.5	%	0.5	%	0.6	%
Patients	0.3	%	0.3	%	0.3	%	0.3	%
Other income	2.3	%	1.9	%	2.4	%	1.9	%
Total	100.0	%	100.0	%	100.0	%	100.0	%

For additional information regarding our payors, see the “Sources of Revenues” section of Item 1, Business, of the 2023 Form 10‑K.

Our Results

Our consolidated results of operations were as follows:


	Three Months Ended September 30,				Percentage Change		Nine Months Ended September 30,				Percentage Change
	2024		2023		2024 vs. 2023		2024		2023		2024 vs. 2023
	(In Millions, Except Percentage Change)
Net operating revenues	$	1,351.0	$	1,206.9	11.9	%	$	3,968.2	$	3,554.4	11.6	%
Operating expenses:
Salaries and benefits	732.1		658.6		11.2	%	2,144.2		1,923.8		11.5	%
Other operating expenses	202.4		183.7		10.2	%	596.2		534.3		11.6	%
Occupancy costs	14.4		14.2		1.4	%	42.6		42.3		0.7	%
Supplies	60.6		53.9		12.4	%	176.7		159.7		10.6	%
General and administrative expenses	54.0		49.8		8.4	%	154.7		148.6		4.1	%
Depreciation and amortization	78.4		67.3		16.5	%	221.6		203.8		8.7	%


Total operating expenses	1,141.9		1,027.5		11.1	%	3,336.0		3,012.5		10.7	%
Loss on early extinguishment of debt	0.4		—		N/A		0.4		—		N/A
Interest expense and amortization of debt discounts and fees	34.9		35.9		(2.8)	%	104.4		108.6		(3.9)	%
Other income	(9.3)		(0.5)		1,760.0	%	(18.0)		(6.8)		164.7	%
Equity in net income of nonconsolidated affiliates	(0.7)		(1.0)		(30.0)	%	(2.8)		(2.3)		21.7	%
Income from continuing operations before income tax expense	183.8		145.0		26.8	%	548.2		442.4		23.9	%
Provision for income tax expense	36.0		30.3		18.8	%	112.6		95.0		18.5	%
Income from continuing operations	147.8		114.7		28.9	%	435.6		347.4		25.4	%
Loss from discontinued operations, net of tax	(0.7)		(1.3)		(46.2)	%	(3.2)		(3.5)		(8.6)	%
Net income	147.1		113.4		29.7	%	432.4		343.9		25.7	%


Less: Net and comprehensive income attributable to noncontrolling interests	(38.9)		(28.1)		38.4	%	(97.6)		(79.5)		22.8	%
Net income attributable to Encompass Health	$	108.2	$	85.3	26.8	%	$	334.8	$	264.4	26.6	%

Operating Expenses as a % of Net Operating Revenues


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Operating expenses:
Salaries and benefits	54.2	%	54.6	%	54.0	%	54.1	%
Other operating expenses	15.0	%	15.2	%	15.0	%	15.0	%
Occupancy costs	1.1	%	1.2	%	1.1	%	1.2	%
Supplies	4.5	%	4.5	%	4.5	%	4.5	%
General and administrative expenses	4.0	%	4.1	%	3.9	%	4.2	%
Depreciation and amortization	5.8	%	5.6	%	5.6	%	5.7	%


Total operating expenses	84.5	%	85.1	%	84.1	%	84.8	%

Additional information regarding our operating results is as follows:


	Three Months Ended September 30,				Percentage Change		Nine Months Ended September 30,				Percentage Change
	2024		2023		2024 vs. 2023		2024		2023		2024 vs. 2023
	(In Millions, Except Percentage Change)
Net operating revenues:
Inpatient	$	1,316.2	$	1,180.5	11.5	%	$	3,864.4	$	3,477.0	11.1	%
Outpatient and other	34.8		26.4		31.8	%	103.8		77.4		34.1	%
Net operating revenues	$	1,351.0	$	1,206.9	11.9	%	$	3,968.2	$	3,554.4	11.6	%
	(Actual Amounts)
Discharges	62,715		57,665		8.8	%	184,659		170,233		8.5	%
Net patient revenue per discharge	$	20,987	$	20,472	2.5	%	$	20,927	$	20,425	2.5	%
Outpatient visits	28,544		28,604		(0.2)	%	87,600		91,208		(4.0)	%
Average length of stay (days)	12.2		12.4		(1.6)	%	12.2		12.4		(1.6)	%
Occupancy %	75.4 %		72.8 %		3.6	%	74.7 %		72.3 %		3.3	%
# of licensed beds	11,041		10,677		3.4	%	11,041		10,677		3.4	%
Occupied beds	8,325		7,773		7.1	%	8,248		7,719		6.9	%
Full-time equivalents (FTEs) - internal	27,938		26,112		7.0	%	27,481		25,562		7.5	%
Contract labor FTEs	430		388		10.8	%	438		441		(0.7)	%
Total FTEs*	28,368		26,500		7.0	%	27,919		26,003		7.4	%
Employees per occupied bed	3.41		3.41		—	%	3.38		3.37		0.3	%

* FTEs included in the above table represent our employees who participate in or support the operations of our hospitals and include FTEs related to contract labor.

We actively manage the productive portion of our Salaries and benefits utilizing certain metrics, including employees per occupied bed, or “EPOB.” This metric is determined by dividing the number of full-time equivalents, including full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period.

In the discussion that follows, we use “same-store” comparisons to explain the changes in certain performance metrics within our financial statements. We calculate same-store comparisons based on hospitals open throughout both the full current periods and prior periods presented. These comparisons include the financial results of market consolidation transactions and capacity expansions (including the addition of satellite and remote hospitals) in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on our results of operations.

Net Operating Revenues

Our consolidated Net operating revenues increased during the three months ended September 30, 2024 compared to the same period of 2023 primarily due to increased volumes. Discharge growth included a 6.8% increase in same-store discharges. Discharge growth from new stores during the three months ended September 30, 2024 compared to the same period of 2023 resulted from our joint ventures in Columbus, Georgia (September 2023), Atlanta, Georgia (May 2024), and Louisville, Kentucky (June 2024), as well as our wholly owned hospitals in Prosper, Texas (November 2023), Fitchburg, Wisconsin (November 2023), Kissimmee, Florida (May 2024), and Johnston, Rhode Island (July 2024). Growth in net patient revenue per discharge during the three months ended September 30, 2024 compared to the same period of 2023 primarily resulted from increase in reimbursement rates and lower revenue reserves related to bad debt partially offset by the change in patient mix. Revenue reserves related to bad debt as a percentage of Net operating revenues decreased during the three months ended September 30, 2024 to 1.9% from 2.2% during the three months ended September 30, 2023 primarily due to strong collections of previously reviewed claims and lower claims review audit activity.

Growth in revenues and discharges during the nine months ended September 30, 2024 were impacted primarily by the same factors as discussed above for the third quarter of 2024. Discharge growth included a 5.7% increase in same-store discharges. Discharge growth from new stores during the nine months ended September 30, 2024 compared to the same period of 2023 also resulted from our joint ventures in Knoxville, Tennessee (March 2023), Owasso, Oklahoma (March 2023), and Bowie, Maryland (June 2023), as well as our wholly owned hospital in Clermont, Florida (April 2023). Growth in net patient revenue per discharge during the nine months ended September 30, 2024 compared to the same period of 2023 primarily resulted from an increase in reimbursement rates partially offset by the change in patient mix.

The increase in outpatient and other revenue during the three and nine months ended September 30, 2024 included an increase of $7.9 million and $25.1 million, respectively, in provider tax revenues (offset by an increase of $4.5 million and $11.8 million, respectively, in provider tax expenses included in Other operating expenses).

Salaries and Benefits

Salaries and benefits increased during the three and nine months ended September 30, 2024 compared to the same periods of 2023 primarily due to salary and benefit cost increases for our employees and increased patient volumes, including an increase in the number of full-time equivalents as a result of our development activities. Salaries and benefits decreased as a percent of Net operating revenues during the three months ended September 30, 2024 compared to the same period of 2023 primarily due to higher volumes. Salaries and benefits decreased as a percent of Net operating revenues during the nine months ended September 30, 2024 compared to the same period of 2023 primarily due to higher volumes and decreases in both contract labor and sign-on and shift bonuses. In order to meet our clinical staffing needs, we have continued to utilize third-party agencies and to pay sign-on and shift bonuses to our employees. While the costs associated with these actions have declined compared to the prior year period, future costs will be affected by labor market conditions and other factors.

Other Operating Expenses

Other operating expenses increased in terms of dollars during the three and nine months ended September 30, 2024 compared to the same periods of 2023 primarily due to increased provider taxes and higher costs resulting from our development activities. Other operating expenses decreased as a percent of Net operating revenues during the three months ended September 30, 2024 compared to the same period of 2023 primarily due to higher volumes.

Other operating expenses during the nine months ended September 30, 2024 included a $10.4 million impairment charge related to the closure of our joint venture inpatient rehabilitation hospital in Eau Claire, Wisconsin. In January 2024, we received notice that our joint venture partner intended to close its acute-care hospital in which our joint venture inpatient rehabilitation hospital was located. We closed that joint venture hospital in February 2024 and incurred a one-time impairment charge of $10.4 million. The impact to Net income attributable to Encompass Health during the nine months ended September 30, 2024 resulting from the impairment was $1.8 million after reductions for Net income attributable to noncontrolling interests of $7.3 million and the Provision for income tax expense of $1.3 million.

General and Administrative Expenses

General and administrative expenses increased in terms of dollars during the three and nine months ended September 30, 2024 compared to the same periods of 2023 primarily due to mark-to-market adjustments on our non-qualified deferred compensation plan and higher salaries, benefits, and software expenses partially offset by lower incentive compensation costs. General and administrative expenses decreased as a percent of Net operating revenues during the three and nine months ended September 30, 2024 compared to the same periods of 2023 primarily due to higher volumes and lower incentive compensation costs.

Depreciation and Amortization

Depreciation and amortization increased during the three and nine months ended September 30, 2024 compared to the same periods of 2023 due to our capital investments. Depreciation and amortization during the nine months ended September 30, 2023 included $6.1 million related to the accelerated amortization of the remaining carrying value of certificate of need (“CON”) assets in South Carolina. In May 2023, the governor of South Carolina signed into law S.164, which repealed the requirement of certain healthcare providers to obtain and/or maintain a CON.

See “Executive Overview” section of this item for information related to our development activity. We expect Depreciation and amortization to increase going forward as a result of our recent and ongoing capital investments.

Income from Continuing Operations Before Income Tax Expense

Our pre-tax income from continuing operations increased during the three and nine months ended September 30, 2024 compared to the same periods of 2023 primarily due to the increase in Net operating revenues as discussed above.

Provision for Income Tax Expense

Our Provision for income tax expense increased during the three and nine months ended September 30, 2024 compared to the same periods of 2023 primarily due to higher Income from continuing operations before income tax expense.

We currently estimate our cash payments for income taxes to be approximately $155 million to $165 million, net of refunds, for 2024. These payments are expected to primarily result from federal and state income tax expenses based on estimates of taxable income for 2024.

In certain jurisdictions, we do not expect to generate sufficient income to use all of the available state net operating losses and foreign tax credits prior to their expiration. This determination is based on our evaluation of all available evidence in these jurisdictions including results of operations during the preceding three years, our forecast of future earnings, and prudent tax planning strategies. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable tax jurisdiction, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state and foreign tax laws and rates.

See Note 7, Income Taxes, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report and Note 16, Income Taxes, to the consolidated financial statements accompanying the 2023 Form 10‑K.

Net Income Attributable to Noncontrolling Interests

The increase in Net income attributable to noncontrolling interests during the three months ended September 30, 2024 compared to the same period of 2023 resulted from increased profitability from certain existing joint venture hospitals. The increase in Net income attributable to noncontrolling interests during the nine months ended September 30, 2024 compared to the same period of 2023 resulted from increased profitability from certain existing joint venture hospitals partially offset by the impact from the impairment related to the closure of our joint venture hospital in Eau Claire, Wisconsin in February 2024, as discussed above.

Liquidity and Capital Resources

Our primary sources of liquidity are cash on hand, cash flows from operations, and borrowings under our revolving credit facility.

The objectives of our capital structure strategy are to ensure we maintain adequate liquidity and flexibility. Pursuing and achieving those objectives allow us to support the execution of our operating and strategic plans and weather temporary disruptions in the capital markets and general business environment. Maintaining adequate liquidity is a function of our unrestricted Cash and cash equivalents and our available borrowing capacity. Maintaining flexibility in our capital structure is a function of, among other things, the amount of debt maturities in any given year, the options for debt prepayments without onerous penalties, and limiting restrictive terms and maintenance covenants in our debt agreements.

Consistent with these objectives, on July 15, 2024, we redeemed $150 million of the outstanding principal balance of our 5.75% Senior Notes due 2025 (the “2025 Notes”) using cash on hand. Pursuant to the terms of the 2025 Notes, this optional redemption was made at a price of par. As a result of this redemption, we recorded a $0.4 million Loss on early extinguishment of debt during the three months ended September 30, 2024.

We have been disciplined in creating a capital structure that is flexible with no significant debt maturities in 2024. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and we have significant availability under our revolving credit facility. We continue to generate strong cash flows from operations, and we have significant flexibility with how we choose to invest our cash and return capital to shareholders.

For additional information, see Note 3, Long-term Debt, to the accompanying condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report, and Note 10, Long-term Debt, to the consolidated financial statements accompanying the 2023 Form 10‑K.

Current Liquidity

As of September 30, 2024, we had $147.8 million in Cash and cash equivalents. This amount excludes $51.1 million in Restricted cash and $131.0 million of restricted marketable securities ($40.6 million included in Other current assets and $90.4 million included in Other long-term assets in our condensed consolidated balance sheet). Our restricted assets pertain primarily to obligations associated with our captive insurance company, as well as obligations we have under agreements with joint venture partners. See Note 5, Cash and Marketable Securities, to the consolidated financial statements accompanying the 2023 Form 10‑K.

In addition to Cash and cash equivalents, as of September 30, 2024, we had approximately $964 million available to us under our revolving credit facility. Our credit agreement governs the substantial majority of our senior secured borrowing capacity and contains a leverage ratio and an interest coverage ratio as financial covenants. Our leverage ratio is defined in our credit agreement as the ratio of consolidated total debt (less cash on hand) to Adjusted EBITDA for the trailing four quarters. In calculating the leverage ratio under our credit agreement, we are permitted to use pro forma Adjusted EBITDA, the calculation of which includes historical income statement items and pro forma adjustments, subject to certain limitations, resulting from (1) dispositions and repayments or incurrence of debt and (2) investments, acquisitions, mergers, amalgamations, consolidations and other operational changes to the extent such items or effects are not yet reflected in our trailing four-quarter financial statements. Our interest coverage ratio is defined in our credit agreement as the ratio of Adjusted EBITDA to consolidated interest expense, excluding the amortization of financing fees, for the trailing four quarters. As of September 30, 2024, the maximum leverage ratio requirement per our credit agreement was 4.75x and the minimum interest coverage ratio requirement was 3.0x, and we were in compliance with these covenants. Based on Adjusted EBITDA for the trailing four quarters and the interest rate in effect under our credit agreement during the three-month period ended September 30, 2024, if we had drawn on the first day and maintained the maximum amount of outstanding draws under our revolving credit facility for that entire period, we would still be in compliance with the maximum leverage ratio and minimum interest coverage ratio requirements.

Effective July 1, 2024, we expanded our existing joint venture with Piedmont Healthcare (“Piedmont”), which we control, by contributing the assets and operations of our previously wholly-owned 70-bed hospital in Augusta, Georgia. Piedmont contributed approximately $90 million on July 1, 2024, which indirectly resulted in Piedmont obtaining a 50% ownership interest in the hospital. For additional information, see Note 1, Basis of Presentation, “Noncontrolling Interests in Consolidated Affiliates,” to the accompanying condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report.

We do not face near-term refinancing risk, as the amounts outstanding under our credit agreement do not mature until 2027, and except for approximately $200 million of our 2025 Notes, our bonds all mature in 2028 and beyond. See Note 3, Long-term Debt, to the accompanying condensed consolidated financial statements, for additional information related to our debt. Also, see the “Contractual Obligations” section below for information related to our contractual obligations as of September 30, 2024.

For a discussion of risks and uncertainties facing us see Item 1A, Risk Factors, under Part II, Other Information, of this report and Item 1A, Risk Factors, of the 2023 Form 10‑K.

Sources and Uses of Cash

The following table shows the cash flows provided by or used in operating, investing, and financing activities (in millions):


	Nine Months Ended September 30,
	2024		2023
Net cash provided by operating activities	$	724.0	$	649.8
Net cash used in investing activities	(449.6)		(394.7)
Net cash used in financing activities	(179.7)		(167.3)
Increase in cash, cash equivalents, and restricted cash	$	94.7	$	87.8

Operating activities. The increase in Net cash provided by operating activities for the nine months ended September 30, 2024 compared to the same period of 2023 primarily resulted from an increase in Net income which was driven by growth in Net operating revenues.

Investing activities. The increase in Net cash used in investing activities during the nine months ended September 30, 2024 compared to the same period of 2023 primarily resulted from increased Purchases of property, equipment, and intangible assets.

Financing activities. The increase in Net cash used in financing activities during the nine months ended September 30, 2024 compared to the same period of 2023 primarily resulted from higher net debt payments and Repurchases of common stock, including fees and expenses partially offset by higher Contributions from noncontrolling interests of consolidated affiliates. Net debt payments during the nine months ended September 30, 2024 included the redemption of $150 million of the outstanding principal balance of our 2025 Notes using cash on hand. See Note 3, Long-term Debt, to the accompanying condensed consolidated financial statements, for additional information related to our debt. Contributions from noncontrolling interests of consolidated affiliates during the nine months ended September 30, 2024 included approximately $90 million from Piedmont discussed above. For additional information related to our stock repurchases, see “Authorizations for Returning Capital to Stakeholders” section below.

Contractual Obligations

Our consolidated contractual obligations as of September 30, 2024 are as follows (in millions):


	Total		Current		Long-term
Long-term debt obligations:
Long-term debt, excluding finance lease obligations (a)	$	2,253.5	$	210.3	$	2,043.2

Interest on long-term debt (b)	487.5		110.3		377.2
Finance lease obligations (c)	470.2		46.6		423.6
Operating lease obligations (d)	306.0		39.5		266.5
Purchase obligations (e)	207.9		57.3		150.6
Total	$	3,725.1	$	464.0	$	3,261.1

(a) Included in long-term debt are amounts owed on our bonds payable and other notes payable. These borrowings are further explained in Note 3, Long-term Debt, accompanying the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report, and Note 10, Long-term Debt, to the consolidated financial statements accompanying the 2023 Form 10‑K.

(b) Interest on our fixed rate debt is presented using the stated interest rate. Interest pertaining to our bonds is included to their respective ultimate maturity dates. Interest related to finance lease obligations is excluded from this line. Amounts exclude amortization of debt discounts, amortization of loan fees, or fees for lines of credit that would be included in interest expense in our condensed consolidated statements of comprehensive income.

(d) We lease approximately 9% of our hospitals as well as other property and equipment under operating leases in the normal course of business. Amounts include interest portion of future minimum operating lease payments. For more information, see Note 8, Leases, to the consolidated financial statements accompanying the 2023 Form 10‑K.

(e) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on Encompass Health and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. Our purchase obligations primarily relate to software licensing and support and contract services. Purchase obligations are not recognized in our condensed consolidated balance sheet.

Our capital expenditures include costs associated with our hospital renovation program, de novo projects, capacity expansions, technology initiatives, and building and equipment upgrades and purchases. During the nine months ended September 30, 2024, we made capital expenditures of approximately $444 million for property, equipment, and intangible assets. During 2024, we expect to spend approximately $595 million to $625 million for capital expenditures using cash on hand and borrowings under our revolving credit facility. Approximately $185 million to $195 million of this budgeted amount is considered nondiscretionary expenditures, which we may refer to in other filings as “maintenance” expenditures. Actual amounts spent will be dependent upon the timing of development projects.

Authorizations for Returning Capital to Stakeholders

In October 2023, February 2024, and May 2024, our board of directors declared cash dividends of $0.15 per share that were paid in January 2024, April 2024, and July 2024, respectively. On July 24, 2024, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.17 per share, that was paid on October 15, 2024 to stockholders of record on October 1, 2024. On October 17, 2024, our board of directors declared a cash dividend of $0.17 per share, payable on January 15, 2025 to stockholders of record on January 2, 2025. We expect quarterly dividends to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board of directors after consideration of various factors, including our capital position and alternative uses of funds. Cash dividends are expected to be funded using cash flows from operations, cash on hand, and availability under our revolving credit facility.

The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement, and (2) either (a) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 2x and our leverage ratio (as defined in our credit agreement) remains less than or equal to 4.50x or (b) our leverage ratio remains in compliance with the leverage ratio covenant and there is capacity under the Available Amount as defined in the credit agreement. The terms of our Notes indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture’s restricted payments covenant to declare and pay dividends. See Note 3, Long-term Debt, to the accompanying condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report, and Note 10, Long-term Debt, to the consolidated financial statements accompanying the 2023 Form 10‑K.

On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. On July 24, 2024, our board of directors approved resetting the aggregate common stock repurchase authorization to $500 million. As of September 30, 2024, approximately $498 million remained under this authorization. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. During the nine months ended September 30, 2024, we repurchased 0.3 million shares of our common stock in the open market for $23.6 million under this repurchase authorization using cash on hand. Future repurchases under this authorization generally are expected to be funded using a combination of cash on hand and availability under our $1 billion revolving credit facility. For additional information, see Part II, Item 2, Unregistered Sales of Equity Securities and Use of Proceeds, of this report.

Supplemental Guarantor Financial Information

Our indebtedness under our credit agreement and the 5.75% Senior Notes due 2025, 4.50% Senior Notes due 2028, 4.75% Senior Notes due 2030, and 4.625% Senior Notes due 2031, (collectively, the “Senior Notes”) are guaranteed by certain consolidated subsidiaries. These guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. The Senior Notes are guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our credit agreement and other capital markets debt. The other subsidiaries of Encompass Health do not guarantee the Senior Notes (such subsidiaries are referred to as the “non-guarantor subsidiaries”).

Summarized financial information is presented below for Encompass Health, the parent company, and the subsidiary guarantors on a combined basis after elimination of intercompany transactions and balances among Encompass Health and the subsidiary guarantors and does not include investments in and equity in the earnings of non-guarantor subsidiaries.


	Nine Months Ended September 30, 2024
	(In Millions)
Net operating revenues	$	2,456.2
Intercompany revenues generated from non-guarantor subsidiaries	76.6
Total net operating revenues	$	2,532.8

Operating expenses	$	2,143.6
Intercompany expenses incurred in transactions with non-guarantor subsidiaries	27.5
Total operating expenses	$	2,171.1

Income from continuing operations	$	201.9
Net income	$	198.7
Net income attributable to Encompass Health	$	198.7


	As of September 30, 2024		As of December 31, 2023
	(In Millions)
Total current assets	$	657.3	$	557.7

Property and equipment, net	$	2,331.4	$	2,201.3
Goodwill	893.1		888.9
Intercompany receivable due from non-guarantor subsidiaries	37.3		187.6
Other noncurrent assets	484.0		466.8
Total noncurrent assets	$	3,745.8	$	3,744.6

Total current liabilities	$	756.1	$	494.7

Long-term debt, net of current portion	$	2,253.2	$	2,604.7
Other noncurrent liabilities	339.9		339.5
Total noncurrent liabilities	$	2,593.1	$	2,944.2

Adjusted EBITDA

Management believes Adjusted EBITDA as defined in our credit agreement is a measure of our ability to service our debt and our ability to make capital expenditures. We reconcile Adjusted EBITDA to Net cash provided by operating activities and to Net income.

We use Adjusted EBITDA on a consolidated basis as a liquidity measure. We believe this financial measure on a consolidated basis is important in analyzing our liquidity because it is the key component of certain material covenants contained within our credit agreement, which is discussed in more detail in Note 10, Long-term Debt, to the consolidated financial statements accompanying the 2023 Form 10‑K. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under our credit agreement—our interest coverage ratio and our leverage ratio—could result in our lenders requiring us to immediately repay all amounts borrowed. If we anticipated a potential covenant violation, we would seek relief from our lenders, which would have some cost to us, and such relief might be on terms less favorable to us than those in our existing credit agreement. In addition, if we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to our assessment of our liquidity.

In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows us to add back to consolidated Net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated Net income (1) all unusual or nonrecurring items reducing consolidated Net income (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3) non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4) share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment of debt, and acquisitions, and (7) any restructuring charges and certain pro forma cost savings and synergies related to transactions and initiatives, which in the aggregate are not in excess of 25% of Adjusted Consolidated EBITDA. We also subtract from consolidated Net income all unusual or nonrecurring items to the extent they increase consolidated Net income.

Under the credit agreement, the Adjusted EBITDA calculation does not require us to deduct net income attributable to noncontrolling interests or gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement’s “unusual or nonrecurring” classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, our ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.

Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for Net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2023 Form 10‑K.

Our Adjusted EBITDA was as follows (in millions):

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA


	Nine Months Ended September 30,
	2024		2023
Net cash provided by operating activities	$	724.0	$	649.8

Interest expense and amortization of debt discounts and fees	104.4		108.6
Gain (loss) on sale of investments, excluding impairments	5.8		(0.9)
Equity in net income of nonconsolidated affiliates	2.8		2.3
Net income attributable to noncontrolling interests in continuing operations	(97.6)		(79.5)
Amortization of debt-related items	(7.3)		(7.1)
Distributions from nonconsolidated affiliates	(3.1)		(0.6)
Current portion of income tax expense	110.5		97.9
Change in assets and liabilities	(19.1)		(58.9)
Cash used in operating activities of discontinued operations	3.7		4.6


State regulatory change impact on noncontrolling interests	—		(2.2)
Asset impairment impact on noncontrolling interests	(7.3)		—
Change in fair market value of equity securities	(2.7)		2.1


Adjusted EBITDA	$	814.1	$	716.1

Reconciliation of Net Income to Adjusted EBITDA


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net income	$	147.1	$	113.4	$	432.4	$	343.9
Loss from discontinued operations, net of tax, attributable to Encompass Health	0.7		1.3		3.2		3.5
Net income attributable to noncontrolling interests included in continuing operations	(38.9)		(28.1)		(97.6)		(79.5)
Provision for income tax expense	36.0		30.3		112.6		95.0
Interest expense and amortization of debt discounts and fees	34.9		35.9		104.4		108.6


Loss on disposal or impairment of assets	0.6		2.2		11.3		3.7
Depreciation and amortization	78.4		67.3		221.6		203.8
Loss on early extinguishment of debt	0.4		—		0.4		—
Stock-based compensation	12.9		13.7		35.8		37.2



State regulatory change impact on noncontrolling interests	—		—		—		(2.2)
Change in fair market value of equity securities	(2.8)		1.5		(2.7)		2.1
Asset impairment impact on noncontrolling interests	—		—		(7.3)		—

Adjusted EBITDA	$	269.3	$	237.5	$	814.1	$	716.1

For additional information see the “Results of Operations” section of this Item.

Recent Accounting Pronouncements

For information regarding recent accounting pronouncements, see Note 1, Basis of Presentation, to our condensed consolidated financial statements included under Part I, Item 1, Financial Statements (Unaudited), of this report.

Item 4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, an evaluation was carried out by our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended. Based on our evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control Over Financial Reporting

There have been no changes in our Internal Control over Financial Reporting during the quarter ended September 30, 2024 that have a material effect on our Internal Control over Financial Reporting.

PART II. OTHER INFORMATION

Item 1.Legal Proceedings

We provide services in the highly regulated healthcare industry. Furthermore, operating inpatient rehabilitation hospitals requires significant staffing and involves intensive therapy for individuals suffering from significant physical or cognitive disabilities or injuries. In the ordinary course of our business, we are subject to regulatory and other governmental audits and investigations and are party to various legal actions, proceedings, and claims, including employment and personal injury claims. These matters could potentially subject us to sanctions, damages, recoupments, fines, and other penalties. Some of these matters have been material to us in the past, and others in the future may, either individually or in the aggregate, be material and adverse to our business, financial position, results of operations, and liquidity.

Additionally, the False Claims Act (the “FCA”) allows private citizens, called “relators,” to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as “qui tam” actions, are common in the healthcare industry and can involve significant monetary damages, fines, attorneys’ fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. It is possible that qui tam lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or prevented by existing law or court order from discussing or disclosing the filing of such suits. Therefore, from time to time, we may be party to one or more undisclosed qui tam cases brought pursuant to the FCA.

Information relating to certain legal proceedings in which we are involved is included in Note 9, Contingencies and Other Commitments, to the condensed consolidated financial statements contained in Part I, Item 1, Financial Statements (Unaudited), of this report and should be read in conjunction with the related disclosure previously reported in our Annual Report on Form 10‑K for the year ended December 31, 2023 (the “2023 Form 10‑K”).

Item 1A.Risk Factors

There have been no material changes from the risk factors disclosed in Part I, Item 1A, Risk Factors, of the 2023 Form 10-K. However, certain information in those risk factors has been updated by the discussion in the “Executive Overview—Key Challenges” section of Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of this report, which section is incorporated by reference herein.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Purchases of Equity Securities

The following table summarizes our repurchases of equity securities during the three months ended September 30, 2024:


Period	Total Number of Shares (or Units) Purchased(1)	Average Price Paid per Share (or Unit) ($)		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs(2)
July 1 through July 31, 2024	52,506	$	84.63	51,746	$	500,000,000
August 1 through August 31, 2024	26,981	85.38		26,981	497,696,249
September 1 through September 30, 2024	149	91.66		—	497,696,249
Total	79,636	84.90		78,727

(1)Except as noted in the following sentence, the number of shares reported in this column includes the shares purchased under the plan or program as reported in the third column of this table and the shares tendered by employees as payments of the tax liabilities incident to the vesting of previously awarded shares of restricted stock and the exercise price and tax liability incident to the net settlement of an option exercise. In July, 760 shares were purchased pursuant to our Directors’ Deferred Stock Investment Plan. This plan is a nonqualified deferral plan allowing non-employee directors to make advance elections to defer a fixed percentage of their director fees. The plan administrator acquires the shares in the open market which are then held in a rabbi trust. The plan also provides that dividends paid on the shares held for the accounts of the directors will be reinvested in shares of our common stock which will also be held in the trust. The directors’ rights to all shares in the trust are nonforfeitable, but the shares are only released to the directors after departure from our board.

(2) On October 28, 2013, we announced our board of directors authorized the repurchase of up to $200 million of our common stock. The common stock repurchase authorization of an aggregate of $250 million in value, approved by our board on July 24, 2018, was in effect for the period reported in this table. On July 24, 2024, our board approved resetting the aggregate common stock repurchase authorization to $500 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Item 5.Other Information

Insider Trading Arrangements

None.

Item 6.Exhibits

See the Exhibit Index immediately following the signature page of this report.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


			ENCOMPASS HEALTH CORPORATION

			By:			/s/ Douglas E. Coltharp
						Douglas E. Coltharp
						Executive Vice President and Chief Financial Officer

			Date:			November 1, 2024

EXHIBIT INDEX

The exhibits required by Regulation S-K are set forth in the following list and are filed by attachment to this report unless otherwise noted.

No.

Description

3.1.1

Amended and Restated Certificate of Incorporation of Encompass Health Corporation, effective as of January 1, 2018 (incorporated by reference to Exhibit 3.1 to Encompass Health’s Current Report on Form 8-K filed on October 25, 2017).

3.1.2

Certificate of Designations of 6.50% Series A Convertible Perpetual Preferred Stock, as filed with the Secretary of State of the State of Delaware on March 7, 2006 (incorporated by reference to Exhibit 3.1 to Encompass Health’s Current Report on Form 8-K filed on March 9, 2006).

3.2

Amended and Restated Bylaws of Encompass Health Corporation, effective as of December 8, 2022 (incorporated by reference to Exhibit 3.1 to Encompass Health’s Current Report on Form 8-K filed on December 13, 2022).

List of Subsidiary Guarantors.

31.1

Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101

Sections of the Encompass Health Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in XBRL (eXtensible Business Reporting Language), submitted in the following files:

101.INS

XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Label Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)